Evidence map›Paper›PMID 39659928›Full record

ArticleAmerican journal of cancer research2024

RBM15 increase tumor-infiltrating CD4+ T cell in ESCC

Xuyang Lin, Xiao Han, Wubi Zhou, Xiaoxia Gong, Yu Zhou, Qilong Wang, Chengwan Zhang

Abstract read
In one paragraph

Article in American journal of cancer research, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed.

  1. Review
  2. Review
  3. Review
  4. RBM15-mediated mFrontiers in cell and developmental biology · 2025
    Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors.

Xuyang LinDepartment of Stomatology, The Affiliated Huai'an No. 1 People's Hospital of Nanjing Medical University Huai'an 223001, Jiangsu, China.
Xiao HanDepartment of Central Laboratory, The Affiliated Huai'an No. 1 People's Hospital of Nanjing Medical University Huai'an 223001, Jiangsu, China.
Wubi ZhouDepartment of Pathology, The Affiliated Huai'an No. 1 People's Hospital of Nanjing Medical University Huai'an 223001, Jiangsu, China.
Xiaoxia GongSchool of Life Science and Technology, MOE Key Laboratory of Developmental Genes and Human Diseases, Southeast University Nanjing 210000, Jiangsu, China.
Yu ZhouDepartment of Medical Oncology, Cancer Center, The Affiliated Huai'an No. 1 People's Hospital of Nanjing Medical University Huai'an 223001, Jiangsu, China.
Qilong WangDepartment of Central Laboratory, The Affiliated Huai'an No. 1 People's Hospital of Nanjing Medical University Huai'an 223001, Jiangsu, China.
Chengwan ZhangDepartment of Central Laboratory, The Affiliated Huai'an No. 1 People's Hospital of Nanjing Medical University Huai'an 223001, Jiangsu, China.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundCollagen, a primary protein component of the extracellular matrix (ECM), undergoes a notable series of alterations concomitant with the growth of the tumor. Procollagen-lysine,2-oxoglutarate 5-dioxygenase 3 (PLOD3) is involved in the synthesis of collagen and has been associated with a variety of cancers. However, it is unclear how PLOD3 functions in esophageal squamous cell carcinoma (ESCC).

methodsDifferentially expressed genes between ESCC and adjacent normal tissues were identified using proteomic and transcriptomic analyses. These genes were then subjected to survival analysis to identify prognostic markers. Immune cell infiltration in the two subgroups was evaluated. Spearman's correlation analysis was performed to examine the correlation between PLOD3 and RBM15 expression in TCGA-ESCC database. shRNA-mediated approach was used to knockdown RBM15 in ESCC cells. The effects of RBM15 knockdown on PLOD3 expression were assessed by real-time PCR and Western blot. Moreover, COX algorithm was employed to construct a prognostic signature.

resultsPLOD3 was found to be highly expressed in ESCC patients and correlated with a favorable prognosis. Immune cell infiltration estimation indicated tumor-infiltrating CD4+ T cell was increased in PLOD3-high group. Correlation analysis revealed that PLOD3 was associated with RBM15 and was closely related to CD4+ T cell infiltration. Moreover, loss-of-function approaches showed that depletion of RBM15 attenuated PLOD3 expression in ESCC cells. Following univariate and multivariate Cox regression analyses, PLOD3 and RBM15 were identified as a two-gene prognostic signature for ESCC.

conclusionRBM15 enhances tumor-infiltrating CD4+ T Cell abundance in ESCC by regulating PLOD3. Two new independent prognostic factors, PLOD3 and RBM15, may be useful in predicting the prognosis of ESCC.

Indexed as

Esophageal squamous cell carcinomaPLOD3RBM15tumor infiltrating cellstumor microenvironment

Identifiers

PMID39659928
PMCPMC11626265

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.